+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biomarkers in Alzheimer’s Disease - Overview

  • ID: 3066978
  • Report
  • August 2014
  • Region: Global
  • 95 Pages
  • Insight Pharma Reports
Biomarkers in Alzheimer’s Disease is focused on biomarker identification and development in patients with Alzheimer’s Disease. This report focuses on the Alzheimer’s Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Alzheimer’s Disease, Biomarkers in Alzheimer’s Disease captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Experts interviewed in this report include:

- Dr. Jens Wendland, Head of Neuroscience Genetics, Precision Medicine, PharmaTherapeutics, Pfizer Worldwide R&D
- Dr. Howard J. Federoff, Executive Vice President for Health Sciences, Georgetown University
- Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers

Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured in an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.

Finally, Insight Pharma Reports concludes this report with clinical trial and pipeline data featuring targets and products from over 200 companies working in Alzheimer’s Disease.

Note: Product cover images may vary from those shown
Executive Summary

CHAPTER 1: The Focus of this Report

CHAPTER 2: Biomarkers and Their Clinical Utility

What are Biomarkers?
Advantages of Biomarkers
Clinical Endpoints vs. Surrogate Endpoints
Advantages of Biomarkers as Surrogate Endpoints
Disadvantages to Biomarkers as Surrogate Endpoints
How are Biomarkers Validated?

CHAPTER 3: Biomarkers in Neurodegenerative Disorders

CHAPTER 4: Mild Cognitive Impairment and Alzheimer’s Disease

How is it Related to Alzheimer’s Disease?
Conflicting Evidence: Mild Cognitive Impairment or Alzheimer’s Disease?
Biomarkers and Candidates for Alzheimer’s Disease
Cerebrospinal fluid Analysis vs. Plasma Analysis
Current Biomarkers
Phospholipid Biomarkers
Single Nucleotide Polymorphisms and Apolipoprotein E
Testosterone and Hormone Levels
Interview with Dr. Howard Federoff
Interview with Dr. Jens Wendland

CHAPTER 5: Biomarkers for Diagnostics

Atlantic Biomarkers: Research Background
Mass-Spectrometry Assays for Biomarkers
Impact on Healthcare
Interview with Dr. Andreas Jeromin
Company Background
Neurobiomarker Research
Mass Spectrometry-Based Assays

CHAPTER 6: Survey Results

CHAPTER 7: Clinical Trials and Pipeline Information

References
Note: Product cover images may vary from those shown

Loading
LOADING...

Biomarkers have been a heavily studied topic of interest, and recently on the rise is the interest in neurodegenerative disorders, particularly Alzheimer’s Disease. Although there are many techniques used to track neurodegenerative disease progression, this report will primarily focus on blood-based and cerebrospinal fluid-based biomarkers for this disease. In addition to covering extensive background information, this report will also highlight market growth and outlook, and feature clinical trial and pipeline information.

After the introduction, Chapters 2 and 3 highlight background information relevant to the rest of this report and include definitions and elaborate examples of different types of biomarkers used in the clinic. Chapter 2 concludes with market growth, advantages of biomarkers, disadvantages of biomarkers, and validation techniques. Chapters 3 gives a brief overview of neurodegenerative disorders, also speaking to the market growth and rise in interest in biomarkers over the years.

Chapter 4 gives specifics on Alzheimer’s Disease and Mild Cognitive Impairment (MCI), featuring definitions, symptoms, genetic markers, and current research. Alzheimer’s Disease is the most common neurodegenerative disorder among the aging population. Understanding the role of specific proteins, and therefore identifying core biomarkers, is crucial to combating this disease and leading patients on the road to effective therapeutics and treatment options. This chapter provides an extensive amount of detail speaking to genetic targets and their use as biomarkers. Experts interviewed for this section include: Dr. Jens Wendland, Head of Neuroscience Genetics, Precision Medicine, Clinical Research, Pfizer Worldwide R&D, and Dr. Howard J. Federoff, Executive Vice President for Health Sciences, Georgetown University. Each of these interviewees discusses their research and how they are advancing the MCI/Alzheimer’s disease field.

Chapter 5 makes the shift from neurobiomarkers to neurodiagnostics. Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers, provides insight on the diagnostic applications that biomarkers possess, and the company’s impact on healthcare.

Chapter 6 includes an elaborate survey analysis exclusively done for this report. Qualifying participants worked with neurobiomarkers, neurodiagnostics, or both. With over 30 survey figures depicting the general R&D group working in this space, this section provides information including: research demographics, targets under investigation, challenges, advantages, and desired features of future diagnostic applications.

Note: Product cover images may vary from those shown
Adroll
adroll